[Drug therapy of Parkinson's disease].
Myllylä
V
V
Oulun yliopiston lääketieteellinen tiedekunta.
D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D015259:Dopamine Agents / Q000627:therapeutic use; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D018696:Neuroprotective Agents / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy*; D012642:Selegiline / Q000627:therapeutic use
D000978:Antiparkinson Agents; D002800:Cholinesterase Inhibitors; D015259:Dopamine Agents; D008996:Monoamine Oxidase Inhibitors; D018696:Neuroprotective Agents; D012642:Selegiline; D007980:Levodopa